Answers are grounded in this paper and cite their sources.
Sofosbuvir-velpatasvir-voxilaprevir taken for 12 weeks provided high rates of sustained virologic response among patients across HCV genotypes in whom treatment with a DAA regimen had previously failed. (Funded by Gilead Sciences; POLARIS-1 and POLARIS-4 ClinicalTrials.gov numbers, NCT02607735 and NCT02639247 .).
No takes yet. Share an insight, caveat, or question.
Bourlière et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: